Recombinant human interferon gamma therapy for osteopetrosis

https://doi.org/10.1016/S0022-3476(05)82557-0Get rights and content

A defect in leukocytic superoxide formation has been demonstrated in patients with congenital osteopetrosis. This leukocyte defect appears to be related to defective bone resorption. Because recombinant human interferon gamma therapy enhances superoxide production in patients with chronic granulomatous disease, we sought to determine whether a similar strategy could reverse the osteopetrotic condition. Interferon gamma, 1.5 μg/kg three times a week, was administered by subcutaneous injection for 6 months to eight patients with osteopetrosis. Urinary hydroxyproline and urinary calcium excretion increased markedly during therapy in parallel with a significant decrease in trabecular bone volume. Bone marrow scans demonstrated increased bone marrow production. The hemoglobin concentration, platelet count, and leukocyte production of superoxide increased significantly. No serious infections were encountered during the therapy. These data suggest that interferon gamma administration enhances bone resorption and leukocyte function in patients with osteopetrosis.

References (11)

  • MarksSC

    Congenital osteopetrotic mutations as probes of the origin, structure and function of osteoclasts

    Clin Orthop

    (1984)
  • ReevesJD et al.

    Host defense in infantile osteopetrosis

    Pediatrics

    (1979)
  • BeardCJ et al.

    Neutrophil defect associated with malignant osteopetrosis

    J Lab Clin Med

    (1986)
  • CocciaPF et al.

    Successful bone-marrow transplantation in infantile malignant osteopetrosis

    N Engl J Med

    (1980)
  • KeyLL

    Osteopetrosis: a genetic window into osteoclast function

There are more references available in the full text version of this article.

Cited by (0)

Supported by March of Dimes grant No. 675; U.S. Food and Drug Administration Orphan Drug grant No. FD-R000768; the Children's Hospital Fund of the Medical University of South Carolina, and a General Clinical Research Center grant, Medical University of South Carolina M01-RR-01070-16.

View full text